These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 11787432)
1. Metabolic impact of puberty on the course of type 1 diabetes. Acerini CL; Williams RM; Dunger DB Diabetes Metab; 2001 Sep; 27(4 Pt 2):S19-25. PubMed ID: 11787432 [TBL] [Abstract][Full Text] [Related]
2. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Resmini E; Minuto F; Colao A; Ferone D Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513 [TBL] [Abstract][Full Text] [Related]
4. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Clemmons DR Curr Opin Pharmacol; 2006 Dec; 6(6):620-5. PubMed ID: 17030015 [TBL] [Abstract][Full Text] [Related]
5. Normalization of the IGF-IGFBP axis by sustained nightly insulinization in type 1 diabetes. Ekström K; Salemyr J; Zachrisson I; Carlsson-Skwirut C; Ortqvist E; Bang P Diabetes Care; 2007 Jun; 30(6):1357-63. PubMed ID: 17372150 [TBL] [Abstract][Full Text] [Related]
6. [Growth hormone, insulin-like growth factor and insulin-like growth factor binding protein in young type I diabetes patients with the onset of diabetic angiopathy]. Peczyńska J; Urban M; Głowińska B; Urban B Pol Merkur Lekarski; 2003 Apr; 14(82):336-9. PubMed ID: 12868196 [TBL] [Abstract][Full Text] [Related]
8. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans. Dupre J Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic aspects of growth hormone and insulin-like growth factor-I treatment on visceral fat and insulin sensitivity in adults. Yuen KC; Dunger DB Diabetes Obes Metab; 2007 Jan; 9(1):11-22. PubMed ID: 17199714 [TBL] [Abstract][Full Text] [Related]
10. Increasing urine albumin excretion is associated with growth hormone hypersecretion and reduced clearance of insulin in adolescents and young adults with type 1 diabetes: the Oxford Regional Prospective Study. Amin R; Williams RM; Frystyk J; Umpleby M; Matthews D; Orskov H; Dalton RN; Dunger DB Clin Endocrinol (Oxf); 2005 Feb; 62(2):137-44. PubMed ID: 15670188 [TBL] [Abstract][Full Text] [Related]
11. Treatment with insulin glargine does not suppress serum IGF-1. Slawik M; Schories M; Busse Grawitz A; Reincke M; Petersen KG Diabet Med; 2006 Jul; 23(7):814-7. PubMed ID: 16842489 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Petersen KR Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723 [TBL] [Abstract][Full Text] [Related]
13. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control. Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156 [TBL] [Abstract][Full Text] [Related]
14. Estrogen and type 1 diabetes mellitus. Codner E Pediatr Endocrinol Rev; 2008 Dec; 6(2):228-34. PubMed ID: 19202509 [TBL] [Abstract][Full Text] [Related]
15. Profound changes in the GH-IGF-I system in adolescent girls with IDDM: can IGFBP1 be used to reflect overall glucose regulation? Halldin MU; Hagenäs L; Tuvemo T; Gustafsson J Pediatr Diabetes; 2000 Sep; 1(3):121-30. PubMed ID: 15016222 [TBL] [Abstract][Full Text] [Related]
16. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes. Baxter MA Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296 [TBL] [Abstract][Full Text] [Related]
17. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Hermansen K; Davies M Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147 [TBL] [Abstract][Full Text] [Related]
18. Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus. Christ ER; Carroll PV; Albany E; Umpleby AM; Lumb PJ; Wierzbicki AS; Sönksen PH; Russell-Jones DL Am J Physiol Endocrinol Metab; 2002 May; 282(5):E1154-62. PubMed ID: 11934682 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628 [TBL] [Abstract][Full Text] [Related]
20. Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults. Yuen KC; Dunger DB Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S55-61. PubMed ID: 16624605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]